TABLE 1.
Demographic and clinical characteristics of critically ill participants overall and by COVID‐19 status, February–June 2020
| Total (n = 300) | COVID+ (n = 200) | COVID− (n = 100) | P value a | |
|---|---|---|---|---|
| Age (years) | 60 ± 16 | 60 ± 16 | 60 ± 16 | .69 |
| BMI (kg/m2) | 31 ± 12 | 32 ± 9 | 30 ± 17 | .25 |
| Male | 180 (60%) | 120 (60%) | 60 (60%) | 1.0 |
| Caucasian | 109 (36%) | 61 (31 %) | 48 (48%) | .005 |
| African American | 170 (57%) | 121 (61%) | 49 (49%) | |
| Other | 21 (7%) | 18 (9%) | 3 (3%) | |
| Clinical characteristics | ||||
| Hypertension | 205 (68%) | 143 (72%) | 62 (62%) | .10 |
| Systolic HF | 44 (15%) | 17 (9%) | 27 (27%) | .0001 |
| Diastolic HF | 68 (23%) | 34 (17%) | 34 (34%) | .001 |
| Coronary artery disease | 59 (20%) | 33 (17%) | 26 (26%) | .05 |
| Atrial fibrillation | 23 (7%) | 9 (5%) | 14 (14%) | .004 |
| Diabetes | 127 (42%) | 93 (47%) | 34 (34%) | .04 |
| Chronic kidney disease | 51 (17%) | 28 (14%) | 23 (23%) | .05 |
| Stroke | 36 (12%) | 19 (10%) | 17 (17%) | .06 |
| COPD | 54 (18%) | 24 (12%) | 30 (30%) | .0001 |
| Cirrhosis | 10 (3%) | 1 (1%) | 9 (9%) | .0001 |
| Obstructive sleep apnea | 35 (12%) | 23 (12%) | 12 (12%) | .90 |
| Tobacco abuse | 102 (34%) | 52 (26%) | 50 (50%) | .0001 |
| Outpatient medications | ||||
| ACE‐I or ARB | 85 (28%) | 56 (28%) | 29 (29%) | .88 |
| Beta‐blocker | 103 (34%) | 56 (28%) | 47 (47%) | .001 |
| Aspirin | 86 (28%) | 53 (27%) | 33 (33%) | .25 |
| P2Y12 inhibitor | 25 (8%) | 15 (8%) | 10 (10%) | .47 |
| Peak inpatient laboratory values | ||||
| D‐dimer (ng/mL) | 3100 ± 4232 | 3542 ± 4664 | 1861 ± 2290 | .02 |
| CRP (mg/L) | 176 ± 116 | 200 ± 113 | 93 ± 86 | .0001 |
| BNP (pg/mL) | 474 ± 690 | 331 ± 566 | 732 ± 812 | .0001 |
| hs troponin (ng/L) | 968 ± 4557 | 549 ± 1599 | 1906 ± 7795 | .03 |
| Inpatient therapies | ||||
| Vasopressor use | 180 (60%) | 142 (71%) | 38 (38%) | .0001 |
| Mechanical ventilation | 190 (63%) | 150 (75%) | 40 (40%) | .0001 |
| Outcomes | ||||
| New ATA | 51 (17%) | 32 (16%) | 19 (19%) | .51 |
| Death | 86 (29%) | 66 (33%) | 20 (20%) | .02 |
Values are mean ± SD or n (%).
Abbreviations: ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ATA, atrial tachyarrhythmia; BMI, body mass index; BNP, brain natriuretic peptide; COPD, chronic obstructive pulmonary disease; COVID, coronavirus disease; CRP, c‐reactive protein; diastolic HF, diastolic heart failure; hs troponin, high‐sensitivity troponin; systolic HF, systolic heart failure.
a P value comparing COVID+ versus COVID−.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.